Scoping review protocol on the impact of antimicrobial resistance on cancer management and outcomes

Abstract

IntroductionAntimicrobial resistance (AMR) is a growing global public health concern and is becoming a significant challenge in the management of patients with cancer. Due to the immunosuppressive nature of cancer treatment, infection is a common complication and the necessary high usage of antibiotics increases the risk of AMR. Failure to adequately prevent and treat infection in patients with cancer as a result of AMR can increase the morbidity and mortality of the disease. The objective of this scoping review is to understand the relationship between AMR and cancer in order to develop effective antimicrobial stewardship in this patient population and minimise the detrimental effects of AMR on cancer outcomes.Methods and analysisThis scoping review will follow the Arksey and O’Malley methodology framework. An exploratory review of the literature on antibiotic resistance in cancer care will help to define the research questions (stage 1). A broad range of electronic databases (MEDLINE ALL, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews and Embase) and search terms will be used to retrieve relevant articles published between 2000 and 2021 (stage 2). Studies will be systematically selected based on the eligibility criteria by two independent reviewers (stage 3). The titles and abstracts will be appraised to determine whether articles meet the eligibility criteria. This will be followed by screening of the full texts and only relevant publications will be retrieved. Data will then be extracted, collated and charted (stage 4); and the summary of aggregated results will be presented (stage 5).Ethics and disseminationAs this scoping review will collect and synthesise data from publicly available sources, no ethics review is required. When data collection and summarisation is completed, results will be disseminated through peer-reviewed publication and the key findings of the review will be presented at relevant conferences.

Antibiotic Resistance related Mortality, Length of Hospital Stay, and Disability-Adjusted Life Years at select Tertiary Hospitals in Uganda:A retrospective study

“…On the other hand, we had only few cancer patients in the study as the study was done in a general ward setting. Cancer is a recognized immune suppressive condition including the immune suppressive effect of its treatment while surgery or bone marrow related cancer treatments rely on effective infection prevention or treatment (34). Fifty percent (50%) of cancer deaths are due to infections but deaths due to AMR have not been well described (35).…”

Implementing a 4% EDTA Central Catheter Locking Solution as a Quality Improvement Project in a Large Canadian Hospital

“…15 Other than the high mortality and morbidity risk, CLABSIs also influence antimicrobial resistance, which is significantly higher in oncology patients than in nononcology counterparts, adding another layer of complexity. 16,17 Hamilton Health Sciences (HHS) is a network of 7 hospitals and an oncology center located in Hamilton, Ontario, Canada, providing health care services to the surrounding Hamilton and Niagara regions. In the past, the CLABSI corporate rates at HHS were 3.00/1000 catheter days in critical care settings.…”

“…New data from Canada have confirmed that patients with CLABSIs face an increased mortality risk, with 1 in 3 patients succumbing within 30 days of the initial positive culture 15. Other than the high mortality and morbidity risk, CLABSIs also influence antimicrobial resistance, which is significantly higher in oncology patients than in nononcology counterparts, adding another layer of complexity 16,17…”